Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.35 |
| ▸ | FABP7 | O15540 | 2/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26071690 | 0.86 | MDM4 (0.38) | MDM4TP53FABP5FABP7MDM2 | |
| SCHEMBL23042936 | 0.84 | MDM4 (0.37) | MDM4TP53FABP5FABP7MDM2 | |
| SCHEMBL29879964 | 0.84 | MDM4 (0.37) | MDM4TP53FABP5FABP7MDM2 | |
| SCHEMBL7517501 | 0.84 | MDM4 (0.37) | MDM4TP53FABP5FABP7MDM2 | |
| SCHEMBL8494693 | 0.80 | FABP5 (0.41) | MDM4TP53FABP5FABP7MDM2 | |
| SCHEMBL29722201 | 0.79 | MDM4 (0.39) | MDM4TP53FABP5FABP7CASP3 | |
| SCHEMBL17991592 | 0.79 | SIRT2 (0.47) | MDM4TP53FABP5FABP7MDM2 | |
| SCHEMBL21837523 | 0.79 | SIRT2 (0.47) | MDM4TP53FABP5FABP7MDM2 | |
| SCHEMBL29381608 | 0.79 | SIRT2 (0.47) | MDM4TP53FABP5FABP7MDM2 | |
| SCHEMBL4428638 | 0.79 | FABP5 (0.40) | MDM4TP53FABP5FABP7MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858538-B1 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS LTD (US) | 2019-03-27 | — | — | EP | disclosed |
| US-9598463-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150274778-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS, LTD. | 2015-10-01 | — | — | US | disclosed |
| US-8907056-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130338085-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS, LTD. | 2013-12-19 | — | — | US | disclosed |
| US-8492518-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS LTD. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8293870-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS LTD (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2399599-A2 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | Biomarck Pharmaceuticals, Ltd. (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100197607-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | WILLIAMS, MASON L. | 2010-08-05 | — | — | US | disclosed |
| US-20090275520-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | WILLIAMS, MASON L. | 2009-11-05 | — | — | US | disclosed |
| US-7524926-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1858538-A2 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | Biomarck Pharmaceuticals, Ltd. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060205664-A1 | Mucin hypersecretion inhibitors and methods of use | WILLIAMS, MASON L. | 2006-09-14 | — | — | US | disclosed |
| WO-2006078899-A2 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2006-07-27 | — | — | WO | disclosed |